Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
It helps maintain hormonal balance and eliminates excess hormones to prevent their accumulation
To obecnie najskuteczniejszy lek odchudzajcy na rynku , wykazujcy rednie redukcje masy ciaa rzdu 10-15%, a w wysokich dawkach nawet powyej 20%
[Mayo Clinic] Ghasemian M, Owlia S, Owlia MB
Current options and future directions for NAFLD and NASH treatment
